Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Wearable patch sensors (smart patches) are rising in popularity, as they offer a wide range of options for medical diagnosis
Subscribe To Our Newsletter & Stay Updated
